Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5595303 | The American Journal of Cardiology | 2017 | 4 Pages |
Abstract
Clinical outcome is generally poor when stents are implanted at right coronary artery ostial lesion (RCAos). We compared the clinical outcome between the first-generation drug-eluting stent (first DES) and second-generation drug-eluting stent (second DES) used for RCAos. Consecutive 88 patients who underwent percutaneous coronary interventions of de novo RCAos using the first DES (33 patients) or second DES (55 patients) were analyzed. The incidence of major adverse cardiac events (MACE) defined as the composite of cardiac death, myocardial infarction attributed to right coronary artery, and target lesion revascularization within 2.5 years was compared. The incidence of MACE was significantly lower in second DES (11% vs 36%, p = 0.010) than that in the first DES. Multivariate analysis revealed use of second DES (odds ratio 0.24, 95% CI 0.11 to 0.93, p = 0.008) alone was significantly associated with MACE. In conclusion, second DES revealed better clinical outcome than the first DES when used in de novo RCAos.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Ryuta MD, Yasunori MD, PhD, Yuji MD, Kuniaki MD, Ayaka BSc, Keisuke MD, Yasuharu MD, PhD, Akio MD, PhD, Kazunori MD, PhD, Yoshiharu MD, PhD, Yoshio MD, PhD,